Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

striking-image-jpg.jfifHIV infects and damages the immune system. Antiretroviral therapy (ART) restores health and life expectancy for HIV-infected individuals and global efforts to increase access to ART have led to a substantial fall in AIDS deaths and new infections.

However, ART does not clear HIV from the body and is still unavailable to millions of people. HIV is able to gain a foothold because it evades immune responses from the earliest stages of infection, while simultaneously seeding long-lived target cells (CD4+ T cells) in which it can remain dormant for many years.

Consequently, patients need to take antiretroviral drugs for life. The goal of our research is to develop vaccines and immune-based therapies to improve control of HIV and ultimately, clear infection.